Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.51 |
| ▸ | FEN1 | P39748 | 1/20 | 0.51 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 12/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026962 | 0.86 | F2 (0.39) | F2PRSS1PRSS2PRSS3KDM4E | |
| SCHEMBL4026333 | 0.82 | ERCC1 (0.45) | ERCC1FEN1ERCC4 | |
| SCHEMBL4024448 | 0.81 | F2 (0.39) | F2PRSS1PRSS2PRSS3ALDH1A1 | |
| SCHEMBL4028450 | 0.81 | FEN1 (0.51) | ERCC1FEN1ERCC4KDM4E | |
| SCHEMBL4025980 | 0.80 | ERCC1 (0.48) | ERCC1FEN1ERCC4ALDH1A1 | |
| SCHEMBL4025695 | 0.79 | ERCC1 (0.49) | ERCC1FEN1ERCC4KDM4EALDH1A1 | |
| SCHEMBL4028018 | 0.79 | ERCC1 (0.49) | ERCC1FEN1ERCC4KDM4EALDH1A1 | |
| SCHEMBL4028016 | 0.79 | FEN1 (0.58) | ERCC1FEN1ERCC4ALDH1A1 | |
| SCHEMBL4030403 | 0.79 | ERCC1 (0.56) | ERCC1FEN1ERCC4HPGD | |
| SCHEMBL4027570 | 0.78 | ERCC1 (0.55) | ERCC1FEN1ERCC4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470113-B1 | PYRIMIDINONE VIRAL POLYMERASE INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-01-07 | — | — | EP | claimed |
| US-20050130997-A1 | Pyrimidinone viral polymerase inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2005-06-16 | — | — | US | claimed |
| EP-1470113-B1 | PYRIMIDINONE VIRAL POLYMERASE INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-01-07 | — | — | EP | disclosed |
| US-20050130997-A1 | Pyrimidinone viral polymerase inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130997-A1 | Pyrimidinone viral polymerase inhibitors | POLR2A, POLR1E, POLR2E | ERCC1 3181/4885FEN1 343/4885ERCC4 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.